Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MT-8421 |
Synonyms | |
Therapy Description |
MT-8421 is an engineered toxin body that targets regulatory T-cells expressing high levels of CTLA-4, potentially resulting in decreases in regulatory T-cells in the tumor microenvironment and increased proliferation of CD8- and CD4-positive T-cells (Journal for ImmunoTherapy of Cancer (2022), 83 (Supplement 2): 817). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MT-8421 | MT8421|MT 8421 | CTLA4 Antibody 31 | MT-8421 is an engineered toxin body that targets regulatory T-cells expressing high levels of CTLA-4, potentially resulting in decreases in regulatory T-cells in the tumor microenvironment and increased proliferation of CD8- and CD4-positive T-cells (Journal for ImmunoTherapy of Cancer (2022), 83 (Supplement 2): 817). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06034860 | Phase I | MT-8421 + Nivolumab MT-8421 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | Terminated | USA | 0 |